What is Nexgel Inc Wt Exp 120126's earnings per share (EPS)?

Nexgel Inc Wt Exp 120126 (NXGLW) reported diluted earnings per share of $-0.38 for fiscal year 2025. This represents a 24.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Nexgel Inc Wt Exp 120126 Financials

NXGLW

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE December

This page shows Nexgel Inc Wt Exp 120126 (NXGLW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI NXGLW FY2025 2026-04-22

Revenue growth is lifting gross economics, but commercial overhead and inventory-funded liquidity still leave the business dependent on outside capital.

The biggest change in FY2025 is cash conversion: free cash burn fell to -$1.4M from -$4.3M. Because net loss changed much less year over year, the smaller cash drain says reported losses are starting to convert more cleanly into cash use, helped by lighter reinvestment rather than a solved profitability problem.

From FY2023 to FY2025, gross margin expansion from 9.2% to 39.5% shows the product-level economics improved sharply as volume scaled. Operating margin also narrowed from -85.0% to -29.4%, but SG&A still ran above gross profit, so growth is covering fixed costs only partway.

FY2025 liquidity is more inventory-backed than cash-backed: cash was just $317K against current liabilities of $3.0M. The 1.5x current ratio looks less roomy once you notice inventory at $2.1M, which means near-term flexibility depends on turning stock into cash and continuing to access financing.

Financial Health Signals

Financial Profile 37/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Nexgel Inc Wt Exp 120126's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Nexgel Inc Wt Exp 120126 has an operating margin of -29.3%, meaning the company retains $-29 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -40.9% the prior year.

Growth

100

Nexgel Inc Wt Exp 120126's revenue surged 31.5% year-over-year to $11.4M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

Nexgel Inc Wt Exp 120126 carries a low D/E ratio of 0.13, meaning only $0.13 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Nexgel Inc Wt Exp 120126's current ratio of 1.47 is below the typical benchmark, resulting in a score of 25/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Cash Flow

While Nexgel Inc Wt Exp 120126 generated -$1.3M in operating cash flow, capex of $68K consumed most of it, leaving -$1.4M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Nexgel Inc Wt Exp 120126 generates a -67.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -57.0% the prior year.

Piotroski F-Score Neutral

5/9

Nexgel Inc Wt Exp 120126 passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.44x

For every $1 of reported earnings, Nexgel Inc Wt Exp 120126 generates $0.44 in operating cash flow (-$1.3M OCF vs -$3.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-98.6x

Nexgel Inc Wt Exp 120126 earns $-98.6 in operating income for every $1 of interest expense (-$3.4M vs $34K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$11.4M

YoY+31.5%

5Y CAGR+76.1%

Nexgel Inc Wt Exp 120126 generated $11.4M in revenue in fiscal year 2025. This represents an increase of 31.5% from the prior year.

EBITDA

-$2.9M

YoY+6.9%

Nexgel Inc Wt Exp 120126's EBITDA was -$2.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 6.9% from the prior year.

Net Income

-$3.0M

YoY+8.6%

Nexgel Inc Wt Exp 120126 reported -$3.0M in net income in fiscal year 2025. This represents an increase of 8.6% from the prior year.

EPS (Diluted)

$-0.38

YoY+24.0%

Nexgel Inc Wt Exp 120126 earned $-0.38 per diluted share (EPS) in fiscal year 2025. This represents an increase of 24.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$1.4M

YoY+68.0%

Nexgel Inc Wt Exp 120126 generated -$1.4M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 68.0% from the prior year.

Cash & Debt

$317K

YoY-82.5%

5Y CAGR+58.2%

Nexgel Inc Wt Exp 120126 held $317K in cash against $588K in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

YoY+6.6%

Nexgel Inc Wt Exp 120126 had 8M shares outstanding in fiscal year 2025. This represents an increase of 6.6% from the prior year.

Margins & Returns

Gross Margin

39.5%

YoY+7.8pp

5Y CAGR+82.7pp

Nexgel Inc Wt Exp 120126's gross margin was 39.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 7.8 percentage points from the prior year.

Operating Margin

-29.3%

YoY+11.6pp

5Y CAGR+306.0pp

Nexgel Inc Wt Exp 120126's operating margin was -29.3% in fiscal year 2025, reflecting core business profitability. This is up 11.6 percentage points from the prior year.

Net Margin

-26.3%

YoY+11.5pp

5Y CAGR+309.6pp

Nexgel Inc Wt Exp 120126's net profit margin was -26.3% in fiscal year 2025, showing the share of revenue converted to profit. This is up 11.5 percentage points from the prior year.

Return on Equity

-67.3%

YoY-10.3pp

5Y CAGR+3121.5pp

Nexgel Inc Wt Exp 120126's ROE was -67.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 10.3 percentage points from the prior year.

Capital Allocation

R&D Spending

$2K

YoY-97.4%

Nexgel Inc Wt Exp 120126 invested $2K in research and development in fiscal year 2025. This represents a decrease of 97.4% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$68K

YoY-84.7%

5Y CAGR-26.3%

Nexgel Inc Wt Exp 120126 invested $68K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 84.7% from the prior year.

NXGLW Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$11.4M+31.5%	$8.7M+112.5%	$4.1M+99.7%	$2.0M+32.0%	$1.6M+130.1%	$674K
Cost of Revenue	$6.9M+16.4%	$5.9M+59.9%	$3.7M+107.3%	$1.8M+16.1%	$1.5M+59.9%	$965K
Gross Profit	$4.5M+64.1%	$2.7M+634.8%	$374K+46.1%	$256K+3100.0%	$8K+102.7%	-$291K
R&D Expenses	$2K-97.4%	$78K-24.3%	$103K-71.9%	$367K+1083.9%	$31K	N/A
SG&A Expenses	$7.9M+26.3%	$6.2M+66.1%	$3.7M+15.8%	$3.2M+27.1%	$2.5M+29.4%	$2.0M
Operating Income	-$3.4M+5.7%	-$3.6M-2.2%	-$3.5M-3.9%	-$3.3M-30.3%	-$2.6M-13.7%	-$2.3M
Interest Expense	$34K-58.0%	$81K+440.0%	$15K-98.9%	$1.3M	N/A	N/A
Income Tax	N/A	N/A	N/A	$0	$0	$0
Net Income	-$3.0M+8.6%	-$3.3M-3.9%	-$3.2M+33.5%	-$4.7M-10.1%	-$4.3M-90.4%	-$2.3M
EPS (Diluted)	$-0.38+24.0%	$-0.50+10.7%	$-0.56+34.1%	$-0.85+41.4%	$-1.45	$-1.05

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$2.6M-5.3%	$2.8M-4.7%	$2.9M+1.7%	$2.9M+2.8%	$2.8M-7.8%	$3.0M+3.5%	$2.9M+104.2%	$1.4M
Cost of Revenue	$1.6M-19.6%	$2.0M+16.9%	$1.7M+4.0%	$1.6M+0.5%	$1.6M-14.9%	$1.9M+6.6%	$1.8M+55.6%	$1.1M
Gross Profit	$1.1M+29.4%	$820K-34.0%	$1.2M-1.2%	$1.3M+5.9%	$1.2M+4.2%	$1.1M-1.3%	$1.2M+294.2%	$293K
R&D Expenses	N/A	N/A	$7K	N/A	$1K	N/A	N/A	$76K
SG&A Expenses	$2.0M-1.0%	$2.0M+4.0%	$2.0M+3.5%	$1.9M-3.6%	$2.0M-0.9%	$2.0M+2.0%	$1.9M+52.9%	$1.3M
Operating Income	-$958K+21.1%	-$1.2M-67.4%	-$725K-14.0%	-$636K+18.1%	-$777K+7.6%	-$841K-6.7%	-$788K+25.2%	-$1.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	$16K-20.0%	$20K-33.3%	$30K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$927K+4.4%	-$970K-48.5%	-$653K+1.8%	-$665K+6.6%	-$712K+16.2%	-$850K-22.7%	-$693K+21.7%	-$885K
EPS (Diluted)	$-0.11	N/A	$-0.08+11.1%	$-0.090.0%	$-0.09	N/A	$-0.11+21.4%	$-0.14

NXGLW Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$10.5M-4.8%	$11.0M+10.3%	$10.0M-3.9%	$10.4M-39.0%	$17.0M+652.5%	$2.3M
Current Assets	$4.3M-15.2%	$5.1M+1.2%	$5.1M-32.7%	$7.5M-46.1%	$13.9M+3736.6%	$363K
Cash & Equivalents	$317K-82.5%	$1.8M-33.1%	$2.7M+145.2%	$1.1M-91.8%	$13.3M+41618.8%	$32K
Inventory	$2.1M+20.6%	$1.8M+32.8%	$1.3M+162.7%	$502K+72.5%	$291K+24.9%	$233K
Accounts Receivable	$673K-27.9%	$933K+47.4%	$633K+185.1%	$222K+6.2%	$209K+186.3%	$73K
Goodwill	$1.1M0.0%	$1.1M0.0%	$1.1M+262.7%	$311K0.0%	$311K0.0%	$311K
Total Liabilities	$5.6M+13.6%	$4.9M+2.4%	$4.8M+76.1%	$2.7M-44.5%	$4.9M+124.1%	$2.2M
Current Liabilities	$3.0M+19.7%	$2.5M-3.1%	$2.5M+196.7%	$859K-70.3%	$2.9M+116.8%	$1.3M
Long-Term Debt	$588K-14.2%	$685K+15.5%	$593K+109.5%	$283K	N/A	N/A
Total Equity	$4.5M-22.5%	$5.8M+22.5%	$4.7M-38.5%	$7.6M-36.8%	$12.1M+16921.1%	$71K
Retained Earnings	-$21.0M-16.7%	-$18.0M-22.3%	-$14.7M-27.3%	-$11.6M-69.7%	-$6.8M-172.3%	-$2.5M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$11.6M+10.9%	$10.5M-10.0%	$11.6M+19.7%	$9.7M-7.0%	$10.4M-5.0%	$11.0M+3.9%	$10.6M+8.1%	$9.8M
Current Assets	$5.6M+30.0%	$4.3M-22.6%	$5.6M+34.6%	$4.2M-12.2%	$4.7M-7.3%	$5.1M+10.9%	$4.6M+28.5%	$3.6M
Cash & Equivalents	$2.1M+569.4%	$317K-66.2%	$938K+29.4%	$725K-39.2%	$1.2M-34.0%	$1.8M+70.6%	$1.1M-0.9%	$1.1M
Inventory	$2.3M+7.2%	$2.1M+4.6%	$2.0M+10.9%	$1.8M-1.4%	$1.8M+5.4%	$1.8M-1.5%	$1.8M+23.0%	$1.4M
Accounts Receivable	$662K-1.6%	$673K-19.8%	$839K+11.4%	$753K-18.7%	$926K-0.8%	$933K+4.4%	$894K+47.8%	$605K
Goodwill	$1.1M0.0%	$1.1M0.0%	$1.1M0.0%	$1.1M0.0%	$1.1M0.0%	$1.1M+0.4%	$1.1M-0.4%	$1.1M
Total Liabilities	$7.1M+27.8%	$5.6M-7.8%	$6.0M+29.8%	$4.7M-4.4%	$4.9M-0.7%	$4.9M-12.2%	$5.6M+6.4%	$5.2M
Current Liabilities	$3.3M+12.1%	$3.0M-10.6%	$3.3M+38.1%	$2.4M-4.9%	$2.5M+2.0%	$2.5M-19.0%	$3.0M+15.8%	$2.6M
Long-Term Debt	$563K-4.3%	$588K-4.2%	$614K-3.8%	$638K-3.6%	$662K-3.4%	$685K-3.4%	$709K-3.1%	$732K
Total Equity	$4.0M-10.4%	$4.5M-14.0%	$5.2M+11.0%	$4.7M-10.3%	$5.2M-9.5%	$5.8M+22.8%	$4.7M+12.5%	$4.2M
Retained Earnings	-$21.9M-4.4%	-$21.0M-4.8%	-$20.0M-3.4%	-$19.4M-3.6%	-$18.7M-4.0%	-$18.0M-5.0%	-$17.1M-4.2%	-$16.5M

NXGLW Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$1.3M+66.1%	-$3.9M-19.5%	-$3.2M-8.2%	-$3.0M-8.7%	-$2.8M-52.9%	-$1.8M
Capital Expenditures	$68K-84.7%	$443K-36.4%	$696K+625.0%	$96K-64.3%	$269K-13.8%	$312K
Free Cash Flow	-$1.4M+68.0%	-$4.3M-9.6%	-$3.9M-27.3%	-$3.1M-2.2%	-$3.0M-43.0%	-$2.1M
Investing Cash Flow	-$68K+91.2%	-$775K-117.4%	$4.5M+179.6%	-$5.6M-1979.9%	-$269K+13.8%	-$312K
Financing Cash Flow	$630K-83.2%	$3.7M+889.2%	$379K+110.3%	-$3.7M-122.4%	$16.3M+767.3%	$1.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	-$504K-279.4%	$281K+135.8%	-$785K-92.9%	-$407K-1.8%	-$400K+53.4%	-$859K+29.4%	-$1.2M-73.7%	-$700K
Capital Expenditures	$9K-77.5%	$40K+400.0%	$8K	N/A	N/A	$69K+430.8%	$13K-93.8%	$209K
Free Cash Flow	-$513K-312.9%	$241K+130.4%	-$793K	N/A	N/A	-$928K+24.5%	-$1.2M-35.2%	-$909K
Investing Cash Flow	-$9K+77.5%	-$40K-400.0%	-$8K	N/A	N/A	-$63K-687.5%	-$8K+98.6%	-$586K
Financing Cash Flow	$1.6M+251.5%	-$1.0M-154.0%	$1.9M+4915.0%	-$40K+81.4%	-$215K-112.9%	$1.7M+37.6%	$1.2M+1996.9%	-$64K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

NXGLW Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	39.5%+7.8pp	31.6%+22.5pp	9.2%-3.4pp	12.5%+12.0pp	0.5%+43.7pp	-43.2%
Operating Margin	-29.3%+11.6pp	-40.9%+44.1pp	-85.0%+78.5pp	-163.5%+2.2pp	-165.7%+169.6pp	-335.3%
Net Margin	-26.3%+11.5pp	-37.8%+39.5pp	-77.2%+154.5pp	-231.7%+46.2pp	-277.9%+58.0pp	-335.9%
Return on Equity	-67.3%-10.3pp	-57.0%+10.2pp	-67.2%-5.1pp	-62.1%-26.5pp	-35.7%+3153.1pp	-3188.7%
Return on Assets	-28.7%+1.2pp	-29.9%+1.8pp	-31.7%+14.1pp	-45.8%-20.4pp	-25.4%+74.9pp	-100.3%
Current Ratio	1.47-0.6	2.07+0.1	1.98-6.8	8.74+3.9	4.82+4.5	0.27
Debt-to-Equity	0.13+0.0	0.120.0	0.13+0.1	0.04-0.4	0.41-30.4	30.79
FCF Margin	-12.1%+37.5pp	-49.6%+46.6pp	-96.2%+54.6pp	-150.8%+44.1pp	-194.8%+118.7pp	-313.5%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	40.0%+10.7pp	29.3%-13.1pp	42.4%-1.2pp	43.6%+1.3pp	42.3%+4.9pp	37.5%-1.8pp	39.3%+18.9pp	20.3%
Operating Margin	-36.1%+7.3pp	-43.4%-18.7pp	-24.7%-2.7pp	-22.1%+5.6pp	-27.7%-0.0pp	-27.7%-0.9pp	-26.8%+46.4pp	-73.2%
Net Margin	-35.0%-0.3pp	-34.7%-12.4pp	-22.3%+0.8pp	-23.1%+2.3pp	-25.4%+2.6pp	-27.9%-4.4pp	-23.6%+37.9pp	-61.5%
Return on Equity	-23.2%-1.5pp	-21.8%-9.2pp	-12.6%+1.6pp	-14.2%-0.6pp	-13.7%+1.1pp	-14.8%+0.0pp	-14.8%+6.5pp	-21.2%
Return on Assets	-8.0%+1.3pp	-9.3%-3.7pp	-5.6%+1.2pp	-6.9%-0.0pp	-6.8%+0.9pp	-7.7%-1.2pp	-6.6%+2.5pp	-9.0%
Current Ratio	1.70+0.2	1.47-0.2	1.69-0.0	1.74-0.1	1.88-0.2	2.07+0.6	1.51+0.1	1.36
Debt-to-Equity	0.140.0	0.13+0.0	0.12-0.0	0.140.0	0.130.0	0.12-0.0	0.15-0.0	0.18
FCF Margin	-19.4%-28.0pp	8.6%+35.6pp	-27.0%	N/A	N/A	-30.5%+11.3pp	-41.8%+21.3pp	-63.1%

Similar Companies

Sharps Technology Inc STSSW

INNOVATIVE EYEWEAR INC LUCYW

Nexgel Inc NXGL

$5.4M

Harvard Biosci HBIO

$29.3M

Precision Optics POCI

$60.2M

Frequently Asked Questions

What is Nexgel Inc Wt Exp 120126's annual revenue?

Nexgel Inc Wt Exp 120126 (NXGLW) reported $11.4M in total revenue for fiscal year 2025. This represents a 31.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Nexgel Inc Wt Exp 120126's revenue growing?

Nexgel Inc Wt Exp 120126 (NXGLW) revenue grew by 31.5% year-over-year, from $8.7M to $11.4M in fiscal year 2025.

Is Nexgel Inc Wt Exp 120126 profitable?

No, Nexgel Inc Wt Exp 120126 (NXGLW) reported a net income of -$3.0M in fiscal year 2025, with a net profit margin of -26.3%.

What is Nexgel Inc Wt Exp 120126's EBITDA?

Nexgel Inc Wt Exp 120126 (NXGLW) had EBITDA of -$2.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Nexgel Inc Wt Exp 120126 have?

As of fiscal year 2025, Nexgel Inc Wt Exp 120126 (NXGLW) had $317K in cash and equivalents against $588K in long-term debt.

What is Nexgel Inc Wt Exp 120126's gross margin?

Nexgel Inc Wt Exp 120126 (NXGLW) had a gross margin of 39.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Nexgel Inc Wt Exp 120126's operating margin?

Nexgel Inc Wt Exp 120126 (NXGLW) had an operating margin of -29.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Nexgel Inc Wt Exp 120126's net profit margin?

Nexgel Inc Wt Exp 120126 (NXGLW) had a net profit margin of -26.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Nexgel Inc Wt Exp 120126's return on equity (ROE)?

Nexgel Inc Wt Exp 120126 (NXGLW) has a return on equity of -67.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Nexgel Inc Wt Exp 120126's free cash flow?

Nexgel Inc Wt Exp 120126 (NXGLW) generated -$1.4M in free cash flow during fiscal year 2025. This represents a 68.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Nexgel Inc Wt Exp 120126's operating cash flow?

Nexgel Inc Wt Exp 120126 (NXGLW) generated -$1.3M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Nexgel Inc Wt Exp 120126's total assets?

Nexgel Inc Wt Exp 120126 (NXGLW) had $10.5M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Nexgel Inc Wt Exp 120126's capital expenditures?

Nexgel Inc Wt Exp 120126 (NXGLW) invested $68K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Nexgel Inc Wt Exp 120126 spend on research and development?

Nexgel Inc Wt Exp 120126 (NXGLW) invested $2K in research and development during fiscal year 2025.

How many shares does Nexgel Inc Wt Exp 120126 have outstanding?

Nexgel Inc Wt Exp 120126 (NXGLW) had 8M shares outstanding as of fiscal year 2025.

What is Nexgel Inc Wt Exp 120126's current ratio?

Nexgel Inc Wt Exp 120126 (NXGLW) had a current ratio of 1.47 as of fiscal year 2025, which is considered adequate.

What is Nexgel Inc Wt Exp 120126's debt-to-equity ratio?

Nexgel Inc Wt Exp 120126 (NXGLW) had a debt-to-equity ratio of 0.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Nexgel Inc Wt Exp 120126's return on assets (ROA)?

Nexgel Inc Wt Exp 120126 (NXGLW) had a return on assets of -28.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Nexgel Inc Wt Exp 120126's cash runway?

Based on fiscal year 2025 data, Nexgel Inc Wt Exp 120126 (NXGLW) had $317K in cash against an annual operating cash burn of $1.3M. This gives an estimated cash runway of approximately 3 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Nexgel Inc Wt Exp 120126's Piotroski F-Score?

Nexgel Inc Wt Exp 120126 (NXGLW) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Nexgel Inc Wt Exp 120126's earnings high quality?

Nexgel Inc Wt Exp 120126 (NXGLW) has an earnings quality ratio of 0.44x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Nexgel Inc Wt Exp 120126 cover its interest payments?

Nexgel Inc Wt Exp 120126 (NXGLW) has an interest coverage ratio of -98.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Nexgel Inc Wt Exp 120126?

Nexgel Inc Wt Exp 120126 (NXGLW) scores 37 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.